Charles Schwab Investment Management Inc Voyager Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 123,050 shares of VYGR stock, worth $621,402. This represents 0.0% of its overall portfolio holdings.
Number of Shares
123,050
Previous 137,571
10.56%
Holding current value
$621,402
Previous $464,000
17.67%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding VYGR
# of Institutions
119Shares Held
32.7MCall Options Held
32.9KPut Options Held
22.7K-
Black Rock Inc. New York, NY5.31MShares$26.8 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.8MShares$24.2 Million0.26% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.92MShares$19.8 Million1.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.21MShares$16.2 Million0.0% of portfolio
-
Vestal Point Capital, LP New York, NY1.48MShares$7.45 Million0.24% of portfolio
About Voyager Therapeutics, Inc.
- Ticker VYGR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,647,600
- Market Cap $195M
- Description
- Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...